Gibson Dunn Represented Cogent Biosciences in Concurrent Public Offerings of Common Stock and Convertible Notes with Aggregate Gross Proceeds of $575 Million

Firm News  |  November 17, 2025

---

Gibson Dunn represented Cogent Biosciences, Inc., a clinical-stage biotechnology company, in concurrent public offerings of common stock and convertible notes expected to result in aggregate gross proceeds of $575 million to Cogent.

J.P. Morgan Securities, Jefferies, Leerink Securities, and Guggenheim Securities acted as joint book-running managers for the equity offering, with LifeSci Capital acting as lead manager and Raymond James Acting as co-manager. Jefferies and J.P. Morgan Securities acted as joint book-running managers for the notes offering.

Our team included partners Ryan Murr, Branden Berns, and Stewart McDowell and associates Nick Linke, Candice Johnson, and Jasmine Vitug.